Aescap 2.0 is now open for new investors
Aescap invests in high-growth companies dedicated to develop and market highly innovative medical treatments. It typically invests in those companies that are de-risked from a technology and finance perspective.
Aescap’s latest fund, Aescap 2.0, is a mutual fund investing in public biotech companies. In order to reduce the risks of investing in this sector the fund diversifies its portfolio over several disease areas, different phases of company development as well as geographical areas. The Fund’s objective is to enable the development of next generation medicine and in parallel make an annual net return of 20%+ to its investors.The fund’s ability to outperform the market is the result of a focused investment strategy, investing in 15-20 biotech companies at a time. Another important pillar under our success is the multi-disciplinary set-up of our team, with most team members having been part of the healthcare industry for over 25 years.
Aescap 2.0 is now open to new investors, investors can join or exit the fund on a monthly basis. Please feel free to give us a call at +31 20 570 29 40 for more information or to receive a prospectus.
Best regards on behalf of the Aescap team,
Patrick J.H. Krol